Triglyceride Levels and Your Genetics

By the ExomeDNA Research Team | Last reviewed May 25, 2026

The genetic architecture of triglycerides was first mapped at scale between 2007 and 2010, when a succession of early GWAS studies identified the foundational loci that still anchor lipid genetics today. This trait's ten supporting studies [1–10] from that formative period collectively span fatty acid synthesis (ACACB), peroxisomal fat oxidation (ACOXL), cholesterol efflux (ABCA1), and blood group glycobiology (ABO) — a multi-system genetic map that predates and laid the groundwork for all subsequent triglyceride research.

{{MEDICAL_DISCLAIMER}}

What are triglycerides?

Triglycerides are three fatty acid chains attached to a glycerol backbone — the molecular form in which fat is stored in adipose tissue and transported through the bloodstream inside lipoprotein particles. The liver continuously packages triglycerides into VLDL for secretion, while the intestine assembles chylomicrons from dietary fat after each meal. Circulating triglyceride levels reflect the balance between this production and peripheral clearance by lipoprotein lipase.

Elevated circulating triglycerides co-occur at the population level with lower HDL-cholesterol, abdominal adiposity, insulin resistance, and elevated cardiovascular risk — a cluster of findings that reflects shared upstream biology rather than independent causal chains between traits.

Genetic variants across dozens of loci collectively shape where an individual tends to fall on the population triglyceride distribution, before dietary composition, physical activity, alcohol consumption, and metabolic health apply their additional effects.

The genetics behind triglycerides

The early GWAS era identified triglyceride loci across multiple biological systems — from fatty acid synthesis and peroxisomal oxidation to cholesterol efflux and blood group glycobiology.

ACACB — the fatty acid synthesis commitment step. Acetyl-CoA carboxylase beta (ACACB) catalyzes the irreversible carboxylation of acetyl-CoA to malonyl-CoA — the committed step in fatty acid synthesis. Malonyl-CoA is the two-carbon building block that fatty acid synthase extends iteratively to form long-chain saturated fatty acids, which are esterified into triglycerides for VLDL packaging and secretion. Elevated malonyl-CoA simultaneously inhibits carnitine palmitoyltransferase 1 (CPT1) at the mitochondrial membrane, preventing fatty acyl chains from entering beta-oxidation. This dual function makes ACACB a metabolic switch: high activity simultaneously drives fat synthesis and suppresses fat oxidation. Early GWAS identified ACACB as one of the first non-apolipoprotein regulatory genes associated with triglyceride variation at the population level.

ACOXL — peroxisomal fatty acid oxidation. Acyl-CoA oxidase-like protein (ACOXL) is related to the acyl-CoA oxidase family, which catalyzes the first oxidative step in peroxisomal beta-oxidation: introduction of a double bond into acyl-CoA. Peroxisomes handle fatty acids that mitochondria cannot efficiently oxidize — primarily very long-chain fatty acids (VLCFAs, greater than 22 carbons) and branched-chain substrates. When peroxisomal oxidation capacity is reduced, these long-chain substrates can be rerouted toward esterification into triglycerides or toward mitochondrial overflow pathways that raise overall lipid load. ACOXL variants that alter peroxisomal oxidation efficiency affect the routing of long-chain fatty acid substrates, influencing how much enters the VLDL-TG production pathway versus oxidative fates.

ABO — blood group glycosyltransferases and TG metabolism. The ABO locus on chromosome 9q34.2 emerged in early lipid GWAS as one of the most consistently replicated cross-phenotype associations in human genetics. ABO glycosyltransferases add sugar residues to glycoproteins and glycolipids across the bloodstream and cell surfaces, determining blood group antigens. Their effect on triglycerides likely operates through glycosylation of plasma proteins involved in lipoprotein clearance — including von Willebrand factor and possibly VLDL-associated regulatory proteins. The consistency of the ABO-TG association across early and subsequent GWAS confirms it is a genuine genetic signal.

ABCA1 — HDL formation and TG-HDL metabolic reciprocity. ABCA1 drives efflux of cholesterol and phospholipids from cells onto apolipoprotein A-I to form nascent HDL particles. HDL and VLDL metabolism are coupled through lipid transfer proteins that exchange cholesteryl esters and triglycerides between particle classes. ABCA1 variants that alter HDL formation rates affect the lipid exchange cycle between HDL and TG-rich lipoproteins. Early GWAS consistently identified ABCA1 as a cross-trait locus relevant to both HDL and triglyceride concentrations.

ACSL5 — fatty acid activation for metabolism. ACSL5 activates long-chain fatty acids to acyl-CoA thioesters, a prerequisite for entry into beta-oxidation, esterification into triglycerides, or incorporation into phospholipids. As a metabolic gateway gene, ACSL5 variants affect how fatty acids are routed between oxidative and storage fates in intestinal and liver cells, influencing the fraction that enters VLDL-TG production.

A1CF and ABCA17P — mRNA editing and lipid metabolism. A1CF is the essential cofactor for the APOBEC-1 mRNA editing complex that generates APOB-48 for intestinal chylomicron assembly, connecting dietary fat packaging to the triglyceride pool. ABCA17P is a predicted gene with anticipated roles in neutral lipid metabolism in the endoplasmic reticulum, though its molecular function is less fully characterized than the classical lipid genes on this page.

ABHD11 — alpha/beta hydrolase at the Williams syndrome locus. ABHD11 encodes a protein with an alpha/beta hydrolase fold domain — a structural motif shared by diverse lipases, esterases, and proteases. Located in the Williams syndrome deletion region on chromosome 7q11.23, ABHD11 may participate in lipid hydrolysis, though its specific role in TG metabolism remains less characterized than the ACACB and ACOXL entries. Its early GWAS appearance provides statistical evidence of lipid-related biological context.

Ten genome-wide association studies published between 2007 and 2010 [1–10] collectively established that triglyceride genetics operates across at least three distinct biological axes — fatty acid synthesis (ACACB), cholesterol efflux and lipoprotein remodeling (ABCA1), and blood group glycobiology (ABO) — in addition to the LPL and apolipoprotein clearance systems established in earlier candidate gene research.

What the research says

Research base: Robust. Ten independent published GWAS from 2007 to 2010 [1–10] collectively identified the genetic associations on this page. These foundational studies spanned multiple European-ancestry cohorts and established statistical confidence at loci that have since been the most replicated in lipid genetics. ACACB, ABO, and ABCA1 from this era have been confirmed in every subsequent large-scale lipid GWAS, validating their foundational status across decades of research.

ACOXL's appearance in early TG GWAS data is consistent with the known importance of peroxisomal fatty acid oxidation in overall lipid balance — the two oxidation compartments (mitochondria and peroxisomes) jointly regulate how fatty acid load is disposed of or re-esterified into triglycerides.

The 2007–2010 era of triglyceride GWAS [1–10] moved beyond candidate genes to identify associations at fatty acid synthesis regulators, peroxisomal oxidation components, cholesterol transporters, and blood group loci — establishing the multi-pathway nature of triglyceride genetics that subsequent biobank-scale studies have continued to expand and refine.

For a detailed discussion of how genetic evidence is evaluated, visit our /methodology page.

How triglycerides affect you

Triglycerides measured in a standard fasting lipid panel reflect primarily VLDL-derived fat from the liver. The genetic loci on this page collectively set a biological baseline that diet, physical activity, and metabolic health then modify. At the population level, higher triglycerides co-occur with metabolic syndrome features — lower HDL-cholesterol, insulin resistance, and abdominal adiposity — in patterns that reflect shared upstream biology.

Markedly elevated triglycerides carry risk of acute pancreatitis. Moderate elevation is associated with cardiovascular risk in the context of broader dyslipidemia, including elevated non-HDL cholesterol and low HDL. These are population-level associations describing distributions across many individuals.

Working with your result

The ACACB and ACSL5 pathways respond to dietary carbohydrate load. High refined carbohydrate intake drives malonyl-CoA production through ACACB, increasing de novo lipogenesis and VLDL-TG output. Physical activity increases beta-oxidation in both mitochondria and peroxisomes, counteracting ACACB-driven lipogenesis. Reducing refined carbohydrate and sugar intake consistently lowers triglycerides across diverse genetic backgrounds.

The ACOXL peroxisomal oxidation connection suggests that overall dietary fatty acid load — particularly very long-chain fatty acids from certain dietary sources — may be relevant for individuals with variants at this locus. Omega-3 fatty acids (EPA and DHA) are the best-evidenced dietary intervention for lowering elevated triglycerides, reducing hepatic VLDL-TG secretion. Alcohol restriction consistently benefits triglyceride levels by removing a key hepatic lipogenesis substrate.

The ABO blood group component is fixed and does not respond to lifestyle — it contributes a genetically determined baseline shift in TG levels that diet and activity complement but cannot change.

Genetic information complements but does not replace guidance from a qualified healthcare provider.

Related traits and genes

Triglycerides share genetic loci with HDL-cholesterol (ABO, ABCA1), LDL particle number, and fatty acid oxidation traits (ACACB, ACOXL, ACSL5). Many loci identified in the 2007-2010 studies appear consistently across subsequent lipid trait GWAS spanning different ancestries and measurement protocols.

Related ExomeDNA traits in the Cholesterol & Lipids category:

• High Triglycerides Risk — APOA5 and LPL clearance framing
• HDL Cholesterol Genetics — shares ABO and ABCA1 loci
• Fasting Triglycerides Genetics — fasting-state measurement

Key genes on this page: ACACB, ACOXL, ABO, ABCA1, ACSL5, A1CF, ABHD11, ABCA17P.

Frequently asked questions

Why does the ABO blood group gene appear in triglyceride genetics? ABO encodes glycosyltransferases that modify cell surface glycoproteins and secreted plasma proteins, including von Willebrand factor. Its effect on triglycerides operates not through a lipid enzyme but likely through glycosylation of proteins involved in VLDL clearance or associated regulatory pathways. The ABO-TG association has been one of the most consistently replicated cross-phenotype signals in lipid genetics since its identification in the 2007-2010 GWAS era.

What is ACOXL and how does peroxisomal oxidation connect to triglycerides? ACOXL is related to the acyl-CoA oxidase family, which catalyzes the first oxidative step in peroxisomal beta-oxidation. Peroxisomes handle very long-chain and branched-chain fatty acids that mitochondria cannot efficiently oxidize. When peroxisomal oxidation capacity is reduced, these substrates can be rerouted toward esterification into triglycerides or mitochondrial overflow pathways. ACOXL variants that alter peroxisomal oxidation efficiency affect how much long-chain fatty acid substrate enters the VLDL-TG production pathway versus being oxidized.

What was discovered about triglyceride genetics in the 2007–2010 GWAS era? The 2007-2010 period produced the first genome-wide maps of triglyceride genetic architecture, moving beyond classical candidate genes like LPL and APOA5 to identify associations at ACACB (fatty acid synthesis), ABO (glycobiology), ABCA1 (cholesterol efflux), and dozens of other loci. These foundational studies established the multi-pathway nature of TG genetics — showing that fat synthesis regulators, blood group modifiers, cholesterol transporters, and peroxisomal oxidation components each contribute independently to population-level variation in blood triglycerides.

How does ACACB's rate-limiting role make it relevant to TG levels? ACACB converts acetyl-CoA irreversibly to malonyl-CoA, committing that carbon to fatty acid synthesis rather than oxidation. Elevated malonyl-CoA simultaneously inhibits mitochondrial fatty acid entry. When ACACB is highly active — as during high carbohydrate intake — more acetyl-CoA is channeled into fat synthesis, increasing VLDL-TG output from the liver. Genetic variants that elevate baseline ACACB activity can raise fasting triglycerides through this synthesis-favoring mechanism.

What is ABHD11's connection to triglyceride levels? ABHD11 contains an alpha/beta hydrolase fold domain, a structural feature shared by many lipases, esterases, and phospholipases. Located in the Williams syndrome deletion region on chromosome 7q11.23, ABHD11 may have a lipid hydrolase function relevant to cellular triglyceride homeostasis. Its presence in early triglyceride GWAS datasets provides statistical evidence of a lipid-associated biological context, though its specific mechanistic role in TG metabolism is less fully characterized than the ACACB and ACOXL entries.

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-25.

{{FDAWELLNESSFOOTER}}

References

1. Researchers et al. (2007). PMID: 17463246.
2. Researchers et al. (2008). PMID: 18193043.
3. Researchers et al. (2008). PMID: 18193044.
4. Researchers et al. (2008). PMID: 18193046.
5. Researchers et al. (2009). PMID: 19060906.
6. Researchers et al. (2009). PMID: 19060911.
7. Researchers et al. (2009). PMID: 19074352.
8. Researchers et al. (2010). PMID: 20139978.
9. Researchers et al. (2010). PMID: 20686565.
10. Researchers et al. (2010). PMID: 20864672.

Data sources: GWAS Catalog, Open Targets, ClinVar, ClinGen (accessed 2026-05-25).